Contracts › 75A50126F61002
75A50126F61002: Rtor Bio-Amt-2312: Assessment of the Therapeutic Potential of Chloroquine and Oseltamivir in Two (2) Lethal Models of Influenza a H5N1
Awarded to Lovelace Biomedical Research Institute by Office of Assistant Secretary for Preparedness and Response.
$3.7Mobligated
$3.7Mpotential value
25 April 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50126F61002 |
|---|---|
| Vehicle | 75A50122D00021 |
| Awardee | Lovelace Biomedical Research Institute |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | NM |
| Period of performance | 26 August 2026 to 25 April 2028 |
| Potential end | 25 April 2028 |
| Estimated recompete solicitation | ~Q4 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record